Ajinomoto (2802) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
10 Dec, 2025Executive summary
H1 FY2025 sales were ¥738.8 billion, nearly flat year-over-year, with business profit at ¥86.7 billion and profit attributable to owners up 2% to ¥51.2 billion, aided by exchange differences from the sale of Ajinomoto Althea, Inc.
Progress toward the full-year plan is slightly behind, but management is implementing corrective actions in key segments to achieve FY2025 targets.
Strategic focus remains on evolving ASV initiatives, innovation, and achieving the 2030 roadmap.
No revision to the previously announced financial forecast.
Financial highlights
H1 FY2025 sales: ¥738.8 billion (99.3% of FY2024); business profit: ¥86.7 billion (99.8% of FY2024); profit attributable to owners: ¥51.2 billion (102% of FY2024).
Gross profit increased by ¥10 billion due to improved margins, despite a ¥2 billion decrease from lower sales.
EBITDA margin rose to 17.5%; organic growth rate at 1.9%.
Net cash provided by operating activities rose to ¥93.2 billion from ¥81.8 billion year-over-year.
Basic and diluted EPS were ¥52.18, up from ¥49.47 year-over-year.
Outlook and guidance
Full-year forecast remains unchanged: sales ¥1,618.0 billion (up 5.7% YoY), business profit ¥180.0 billion (up 13.0% YoY), profit attributable to owners ¥120.0 billion (up 70.7% YoY).
Management expects to achieve FY2025 guidance, with significant profit recovery expected in the second half, especially in CDMO, seasonings, and frozen foods.
Annual dividend forecast is ¥48.00 per share post-stock split.
2030 ASV indicators target ROE of 20%, ROIC of 17%, and EBITDA margin of 19% or more.
Latest events from Ajinomoto
- Integrated sustainability and innovation drive growth, decarbonization, and value creation.2802
Investor Day 202616 Mar 2026 - Record sales and profit, raised full-year outlook, and capital gains from asset sales.2802
Q3 20265 Feb 2026 - Record Q1 sales and profit, but net profit fell 12% due to a temporary tax impact.2802
Q1 20252 Feb 2026 - Record sales and profit growth drove forecast upgrades and major shareholder returns.2802
Q2 202516 Jan 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026 - Succession planning and strategic board evolution drive bold 2030 growth and sustainability targets.2802
Investor Day 20254 Dec 2025 - Business profit up 9.7% to ¥47.2bn, led by Functional Materials and Healthcare growth.2802
Q1 202623 Nov 2025 - Record sales and profit, with robust FY2025 growth, major buyback, and 2-for-1 stock split.2802
Q4 202518 Nov 2025 - Medical food sales set to double by 2030, driven by innovation, global reach, and new markets.2802
Investor update14 Nov 2025